Asset Details
Do you wish to reserve the book?
P-557: Additive effect of drospirenone/17-beta estradiol (DRSP/E2) on 24-hour ambulatory blood pressure in hypertensive post-menopausal women receiving enalapril maleate
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P-557: Additive effect of drospirenone/17-beta estradiol (DRSP/E2) on 24-hour ambulatory blood pressure in hypertensive post-menopausal women receiving enalapril maleate
Do you wish to request the book?
P-557: Additive effect of drospirenone/17-beta estradiol (DRSP/E2) on 24-hour ambulatory blood pressure in hypertensive post-menopausal women receiving enalapril maleate
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P-557: Additive effect of drospirenone/17-beta estradiol (DRSP/E2) on 24-hour ambulatory blood pressure in hypertensive post-menopausal women receiving enalapril maleate
2002
Overview
Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP /17-beta estradiol (DRSP/E2). We investigated the additive effect of DRSP/E2 on 24-hour ambulatory blood pressure in 24 post-menopausal women with mild hypertension treated with enalapril maleate (E). Design: Double-blind, randomized, two parallel group trial. Subjects: 24 non-smoking postmenopausal women receiving E 10 mg bid prior to study were randomized to DRSP/E2 + E (n=12) or placebo (P) + E (n=12) for 14 days . Procedures: 24-hour ambulatory systolic and diastolic blood pressure and serum aldosterone were determined on the day prior to first dose of DRSP/E2 or P (Day -1) and on study Day 14. Both systolic (p=.014) and diastolic (p=.007) mean 24-hour ambulatory blood pressures were decreased from baseline in the DRSP/E2 + E group compared to P + E. No change in systolic or diastolic 24-hour ambulatory blood pressures were observed in the P + E group. Aldosterone increased from baseline by 2.6 (4.5) in the DRSP/E2 + E group, and fell by 0.33 (5.5) in the P + E group (p=0.08). Our results suggest a significant additive blood-pressure lowering effect of DRSP/E2 on both systolic and diastolic blood pressure in hypertensive postmenopausal women receiving E consistent with an antimineralocorticoid effect. In view of the negative results of trials of standard HRT, a HRT with antimineralocorticoid effects could offer a novel potential mechanism for reducing cardiovascular endpoints in postmenopausal women.
Publisher
Oxford University Press
